ResearcherKarolinska InstitutetNo recent work listed
Arne Östman
Matched on ORCID iD 0000-0003-3993-0021; OpenAlex author ID A5041272737. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper
Papers 5
- A Novel Pancreatic Cancer Mini-tumor Model to Study Desmoplasia and Myofibroblastic Cancer-Associated Fibroblast Differentiation. Co-author DOI 10.1016/j.gastha.2022.04.019↗
- Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. Co-author DOI 10.1096/fj.201802336r↗
- ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Co-author DOI 10.1126/sciadv.aax2770↗
- Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Last author DOI 10.1038/bjc.2017.140↗
- SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo. Co-author DOI 10.1016/j.ejphar.2015.03.064↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jai Prakash · 4 shared papers, 2015–2019 · strength 0.32
- Paper Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. DOI 10.1096/fj.201802336r↗
- Paper ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancre… DOI 10.1126/sciadv.aax2770↗
- Paper SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo. DOI 10.1016/j.ejphar.2015.03.064↗
- Jonas Schnittert · 3 shared papers, 2017–2019 · strength 0.25
- Paper Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer. DOI 10.1096/fj.201802336r↗
- Paper ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancre… DOI 10.1126/sciadv.aax2770↗
- Paper Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. DOI 10.1038/bjc.2017.140↗
- Carina Strell · 3 shared papers, 2015–2022 · strength 0.25
- Paper A Novel Pancreatic Cancer Mini-tumor Model to Study Desmoplasia and Myofibroblastic Cancer-Associated Fibroblast Differ… DOI 10.1016/j.gastha.2022.04.019↗
- Paper SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo. DOI 10.1016/j.ejphar.2015.03.064↗
- Paper Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. DOI 10.1038/bjc.2017.140↗
- Deby Fajar Mardhian · 2 shared papers, 2019 · strength 0.19
- Praneeth Reddy Kuninty · 2 shared papers, 2017–2019 · strength 0.14
- Marten Hornsveld · 1 shared paper, 2022 · strength 0.13
- Tom J. Harryvan · 1 shared paper, 2022 · strength 0.13
- Lukas J.A.C. Hawinkels · 1 shared paper, 2022 · strength 0.13
- Jeanin Elise van Hooft · 1 shared paper, 2022 · strength 0.13
- Peter ten Dijke · 1 shared paper, 2022 · strength 0.13
- Susanna W.L. de Geus · 1 shared paper, 2019 · strength 0.08
- Peter J.K. Kuppen · 1 shared paper, 2019 · strength 0.08
- Cornelis F.M. Sier · 1 shared paper, 2019 · strength 0.08
- Hanneke W.M. van Laarhoven · 1 shared paper, 2019 · strength 0.08
- Alexander L. Vahrmeijer · 1 shared paper, 2019 · strength 0.08
- Maarten F. Bijlsma · 1 shared paper, 2019 · strength 0.08
- Chern Ein Oon · 1 shared paper, 2015 · strength 0.06
- Carlos Fernández Moro · 1 shared paper, 2017 · strength 0.06
- Dan Calatayud · 1 shared paper, 2017 · strength 0.06
- Rainer Lothar Heuchel · 1 shared paper, 2017 · strength 0.06
- Nicolai A. Schultz · 1 shared paper, 2017 · strength 0.06
- Artur Mezheyeuski · 1 shared paper, 2017 · strength 0.06
- Julia Sidenius Johansen · 1 shared paper, 2017 · strength 0.06
- Matthias J. Löhr · 1 shared paper, 2017 · strength 0.06
- Caroline Sophie Verbeke · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.